CONTROL OF OSTEOGENESIS AND ADIPOGENESIS BY EBF

EBF 对成骨和脂肪生成的控制

基本信息

  • 批准号:
    7195227
  • 负责人:
  • 金额:
    $ 33.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Osteoblasts, the cells that form bone, are mesenchymal in origin and like other mesenchymal lineages arise from pluripotential stem cells through a series of developmental transitions. The osteoblast developmental pathway is only partially understood, particularly in its early stages, where little is know about the cell fate decisions that lead to commitment to the osteoblast lineage. Adipocytes, the cells that produce fat, likely share a common early progenitor with osteoblasts, although little is known about the molecular control of this lineage bifurcation. Growing evidence indicates that transcription factors required for B lymphocyte development from hematopoietic stem cells are critical for proper skeletal development although as yet none have been implicated in osteoblast differentiation. We have discovered that Early B Cell Factor-1 (EBF-1), a transcription factor essential for B cell development, is expressed in osteoblasts and plays a critical role in controlling osteoblast development. EBF-1 deficient mice are runted, have increased bone formation parameters, and display a striking increase in numbers of osteoblasts. Remarkably, these mice also exhibit a dramatic expansion of adipocytes in the medullary canal of long bones. The central hypothesis underlying this proposal is that EBF-1 and its upstream regulatory and downstream target genes are critical for the control of osteoblast and adipocyte development. Our findings suggest that EBF-1 and EBF-1 deficient mice provide a unique opportunity to gain significant molecular insight into the development of these two lineages. The long-term goal of our work is to identify the mechanism(s) by which EBF-1 regulates osteogenesis and adipogenesis. The first step in achieving this goal is a careful analysis of the EBF-1 deficient mice at the histological, morphological, cellular, and molecular level, which will provide the information needed to formulate detailed molecular hypotheses for the role of EBF-1 in bone and fat cell development. Toward this end, we will pursue two Specific Aims: 1) To determine the bone phenotype of EBF-1 deficient mice; and 2) To characterize through a quantitative analysis the functional and molecular properties of EBF-1 deficient osteoblasts, osteoblast precursors, and adipocytes. We anticipate that these experiments will lead to new models for osteoblast development and hence for the potential to discover new anabolic pathways. Such information would be applicable to a wide variety of skeletal defects including age-related osteopenia, post-menopausal osteoporosis, fracture repair, and extended survival of prosthetic implants.
描述(由申请人提供):成骨细胞(形成骨的细胞)是间充质来源的,与其他间充质谱系一样,通过一系列发育转变由多能干细胞产生。成骨细胞发育途径仅部分了解,特别是在其早期阶段,其中对导致承诺成骨细胞谱系的细胞命运决定知之甚少。脂肪细胞,产生脂肪的细胞,可能与成骨细胞共享一个共同的早期祖细胞,尽管对这种谱系分叉的分子控制知之甚少。越来越多的证据表明,造血干细胞的B淋巴细胞发育所需的转录因子是至关重要的适当的骨骼发育,虽然还没有涉及成骨细胞分化。我们已经发现早期B细胞因子-1(EBF-1),一种B细胞发育所必需的转录因子,在成骨细胞中表达并且在控制成骨细胞发育中起关键作用。EBF-1缺陷小鼠发育不良,骨形成参数增加,成骨细胞数量显著增加。值得注意的是,这些小鼠在长骨的髓管中也表现出脂肪细胞的急剧扩张。这一提议的核心假设是EBF-1及其上游调控和下游靶基因对于成骨细胞和脂肪细胞发育的控制至关重要。我们的研究结果表明,EBF-1和EBF-1缺陷小鼠提供了一个独特的机会,以获得显着的分子洞察这两个谱系的发展。我们工作的长期目标是确定EBF-1调节骨生成和脂肪生成的机制。实现这一目标的第一步是在组织学,形态学,细胞和分子水平上仔细分析EBF-1缺陷小鼠,这将提供制定详细的EBF-1在骨和脂肪细胞发育中的作用的分子假设所需的信息。为此,我们将追求两个具体目标:1)确定EBF-1缺陷小鼠的骨表型; 2)通过定量分析表征EBF-1缺陷成骨细胞、成骨细胞前体和脂肪细胞的功能和分子特性。我们预计,这些实验将导致成骨细胞发育的新模型,因此有可能发现新的合成代谢途径。这些信息将适用于各种各样的骨骼缺陷,包括年龄相关的骨质减少,绝经后骨质疏松症,骨折修复和假体植入物的延长生存期。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK C HOROWITZ其他文献

MARK C HOROWITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK C HOROWITZ', 18)}}的其他基金

The Sixth International Conference on Osteoimmunology: Interactions of the Immune and Skeletal Systems
第六届国际骨免疫学会议:免疫与骨骼系统的相互作用
  • 批准号:
    9117878
  • 财政年份:
    2016
  • 资助金额:
    $ 33.08万
  • 项目类别:
The Fifth International Conference on Osteoimmunology: Interactions of the Immune
第五届国际骨免疫学会议:免疫的相互作用
  • 批准号:
    8709156
  • 财政年份:
    2014
  • 资助金额:
    $ 33.08万
  • 项目类别:
Myeloid Lineage Differentiation and Osteoclast Priming by a Novel Pax5 Cytokine
新型 Pax5 细胞因子的骨髓谱系分化和破骨细胞启动
  • 批准号:
    8692538
  • 财政年份:
    2013
  • 资助金额:
    $ 33.08万
  • 项目类别:
Myeloid Lineage Differentiation and Osteoclast Priming by a Novel Pax5 Cytokine
新型 Pax5 细胞因子的骨髓谱系分化和破骨细胞启动
  • 批准号:
    8581522
  • 财政年份:
    2013
  • 资助金额:
    $ 33.08万
  • 项目类别:
CELL CORE
细胞核心
  • 批准号:
    8376753
  • 财政年份:
    2012
  • 资助金额:
    $ 33.08万
  • 项目类别:
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy Balance
骨髓肥胖、矿物质代谢的跨学科研究
  • 批准号:
    8328698
  • 财政年份:
    2011
  • 资助金额:
    $ 33.08万
  • 项目类别:
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy Balance
骨髓肥胖、矿物质代谢的跨学科研究
  • 批准号:
    8698743
  • 财政年份:
    2011
  • 资助金额:
    $ 33.08万
  • 项目类别:
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy Balance
骨髓肥胖、矿物质代谢的跨学科研究
  • 批准号:
    8496032
  • 财政年份:
    2011
  • 资助金额:
    $ 33.08万
  • 项目类别:
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy Balance
骨髓肥胖、矿物质代谢的跨学科研究
  • 批准号:
    8183483
  • 财政年份:
    2011
  • 资助金额:
    $ 33.08万
  • 项目类别:
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism, and Energy Balance
骨髓肥胖、矿物质代谢和能量平衡的跨学科研究
  • 批准号:
    9769004
  • 财政年份:
    2011
  • 资助金额:
    $ 33.08万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 33.08万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 33.08万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 33.08万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 33.08万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 33.08万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 33.08万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 33.08万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 33.08万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 33.08万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 33.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了